-+ 0.00%
-+ 0.00%
-+ 0.00%

CORBUS PHARMACEUTICALS TO REPORT RESULTS FROM PHASE 1A STUDY OF ORAL CB1 INVERSE AGONIST CRB-913 FOR THE TREATMENT FOR OBESITY ON THURSDAY, DECEMBER 11, 2025

Reuters·12/10/2025 21:01:00

Please log in to view news